Page last updated: 2024-10-29

ifosfamide and Bleeding

ifosfamide has been researched along with Bleeding in 42 studies

Research Excerpts

ExcerptRelevanceReference
"Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem."8.84Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. ( Korkmaz, A; Oter, S; Topal, T, 2007)
"Acrolein is the main toxic metabolite of ifosfamide (IFO) that causes urothelial damage by oxidative stress and inflammation."8.31[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10. ( Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN, 2023)
"Hemorrhagic cystitis (HC) is the major dose-limiting adverse effect of the clinical use ifosfamide (IFOS)."7.96α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. ( Almeida, FRC; Cunha, FVM; Gonçalves, RLG; Lima-Júnior, RCP; Lopes, ME; Medeiros, JVR; Nogueira, KM; Oliveira, CPC; Oliveira, FA; Oliveira, LSA; Pereira, VMP; Rezende, DC; Sousa, DP; Sousa, IJO; Sousa-Neto, BPS; Souza, LKM; Wong, DVT, 2020)
"Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites."7.91IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. ( Alouffi, A; Banskota, N; Falcone, FH; Hsieh, MH; Ishida, K; Jardetzky, TS; Le, L; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, R, 2019)
"Hemorrhagic cystitis is an important dose limiting side effect of ifosfamide based cancer chemotherapy."7.81Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice. ( Alencar, VT; Brito, GA; Cunha, FQ; Leite, CA; Lima-Júnior, RC; Magalhães, PJ; Melo, DL; Melo, PH; Mota, JM; Mourão, LT; Ribeiro, RA; Santos, AA; Wong, DV, 2015)
"We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis."7.78Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. ( Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV, 2012)
"Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium."7.77Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011)
"Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)."7.74Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008)
"Ifosfamide (IFS) is an antineoplastic alkylating agent whose major side effect is hemorrhagic cystitis (HC)."7.74Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. ( Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML, 2007)
") in cyclophosphamide (CYP) and ifosfamide (IFS) induced hemorrhagic cystitis (HC)."7.72Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. ( Brito, GA; Costa, AC; Cunha, AN; Filho, JN; Macêdo, FY; Ribeiro, RA; Silveira, ER; Vieira, MM, 2004)
"Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)."7.72Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003)
"We investigated the participation of nitric oxide in ifosfamide induced hemorrhagic cystitis in mice, and the involvement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in the induction of nitric oxide production in this model."7.71Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. ( Brito, GA; Campos, MC; Cunha, FQ; Figueiredo, FC; Freitas, HC; Ribeiro, RA; Santos, CC, 2002)
"Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent."7.69Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."7.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."7.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"To prevent hemorrhagic cystitis induced by ifosfamide, continuous bladder irrigation with 3,000 ml."7.66Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. ( Fujita, J; Kakizoe, T; Matsumoto, K; Murase, T, 1981)
"Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers."5.48Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. ( Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT, 2018)
"The incidence of IFO-induced HC may be associated with the dosage of IFO."5.43A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016)
"The use of oxazaphosphorines (cyclophosphamide, ifosfamide) in the treatment of numerous neoplastic disorders is associated with their essential adverse effect in the form of hemorrhagic cystitis, which considerably limits the safety and efficacy of their pharmacotherapy."4.88Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention . ( Dobrek, Ł; Thor, PJ, 2012)
"Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem."4.84Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. ( Korkmaz, A; Oter, S; Topal, T, 2007)
"Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis."4.82Side effects of ifosfamide. ( Klastersky, J, 2003)
"Acrolein is the main toxic metabolite of ifosfamide (IFO) that causes urothelial damage by oxidative stress and inflammation."4.31[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10. ( Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN, 2023)
"Hemorrhagic cystitis (HC) is the major dose-limiting adverse effect of the clinical use ifosfamide (IFOS)."3.96α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. ( Almeida, FRC; Cunha, FVM; Gonçalves, RLG; Lima-Júnior, RCP; Lopes, ME; Medeiros, JVR; Nogueira, KM; Oliveira, CPC; Oliveira, FA; Oliveira, LSA; Pereira, VMP; Rezende, DC; Sousa, DP; Sousa, IJO; Sousa-Neto, BPS; Souza, LKM; Wong, DVT, 2020)
"Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites."3.91IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. ( Alouffi, A; Banskota, N; Falcone, FH; Hsieh, MH; Ishida, K; Jardetzky, TS; Le, L; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, R, 2019)
"Hemorrhagic cystitis is an important dose limiting side effect of ifosfamide based cancer chemotherapy."3.81Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice. ( Alencar, VT; Brito, GA; Cunha, FQ; Leite, CA; Lima-Júnior, RC; Magalhães, PJ; Melo, DL; Melo, PH; Mota, JM; Mourão, LT; Ribeiro, RA; Santos, AA; Wong, DV, 2015)
"We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis."3.78Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. ( Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV, 2012)
"Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium."3.77Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011)
"Ifosfamide (IFS) is an antineoplastic alkylating agent whose major side effect is hemorrhagic cystitis (HC)."3.74Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. ( Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML, 2007)
"Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)."3.74Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008)
"Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)."3.72Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003)
") in cyclophosphamide (CYP) and ifosfamide (IFS) induced hemorrhagic cystitis (HC)."3.72Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. ( Brito, GA; Costa, AC; Cunha, AN; Filho, JN; Macêdo, FY; Ribeiro, RA; Silveira, ER; Vieira, MM, 2004)
" Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy."3.71U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002)
"We investigated the participation of nitric oxide in ifosfamide induced hemorrhagic cystitis in mice, and the involvement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in the induction of nitric oxide production in this model."3.71Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. ( Brito, GA; Campos, MC; Cunha, FQ; Figueiredo, FC; Freitas, HC; Ribeiro, RA; Santos, CC, 2002)
"Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent."3.69Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996)
"To prevent hemorrhagic cystitis, mesna is typically injected intravenously (i."3.69Combined intravenous and oral mesna in outpatients treated with ifosfamide. ( Goodman, TL; Goren, MP; McKenna, LM, 1997)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."3.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis."3.67Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. ( Hilgard, P; Pohl, J; Stekar, J, 1989)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."3.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"To prevent hemorrhagic cystitis induced by ifosfamide, continuous bladder irrigation with 3,000 ml."3.66Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. ( Fujita, J; Kakizoe, T; Matsumoto, K; Murase, T, 1981)
" This review summarizes dosing schedules and the incidence of hematuria in 47 clinical studies, in which oral mesna was given to at least 1,986 patients who received more than 6,475 courses of ifosfamide."2.39Oral administration of mesna with ifosfamide. ( Goren, MP, 1996)
"Novel therapeutic options to treat hemorrhagic cystitis are needed."1.51IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis. ( Akinwale, J; Alouffi, A; Falcone, FH; Hsieh, MH; Jardetzky, TS; Le, LH; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, RS, 2019)
"Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers."1.48Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. ( Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT, 2018)
"The incidence of IFO-induced HC may be associated with the dosage of IFO."1.43A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016)
" Ifosfamide, although itself the effective antineoplastic drug useful in situations which have proved refractory to cyclophosphamide therapy, has the side-effect toxicities caused by its metabolities that pose clinically a very real problem."1.30Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. ( Konarski, L; Kowalski, P; Kuśnierczyk, H; Radzikowski, C, 1997)
"But pulmonary hemorrhage and respiratory failure resulted in her death 7 months after initial diagnosis."1.30Treatment of primary pure angiosarcoma of ovary with multiple lung metastases: a case report. ( Chao, KC; Juang, CM; Lai, CZ; Lu, CJ; Twu, NF; Yeng, MS, 1999)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19908 (19.05)18.7374
1990's10 (23.81)18.2507
2000's10 (23.81)29.6817
2010's12 (28.57)24.3611
2020's2 (4.76)2.80

Authors

AuthorsStudies
Ferreira, FCS1
Clementino, M1
Rodrigues, FAP1
Veras, HN1
Martins, DS1
Queiroga, ML1
Lima, MA1
Silva, DO1
de Freitas, TM1
Ribeiro, SA1
Mota, MRL1
da Silva, JA1
Lima, AAM1
Havt, A1
Gonçalves, RLG1
Cunha, FVM1
Sousa-Neto, BPS1
Oliveira, LSA1
Lopes, ME1
Rezende, DC1
Sousa, IJO1
Nogueira, KM1
Souza, LKM1
Medeiros, JVR1
Wong, DVT2
Pereira, VMP1
Lima-Júnior, RCP2
Sousa, DP1
Oliveira, CPC1
Almeida, FRC1
Oliveira, FA1
Kamal, M1
Govil, A1
Anand, M1
Abu Jawdeh, BG1
Shah, S1
Dornelas-Filho, AF1
Pereira, VBM1
Nobre, LMS1
Melo, AT1
Silva, CMS1
Wanderley, CWS1
Nour, ML1
Araújo, LCNC1
Silva, RO1
Pinto, FMM1
Bingana, RD1
Souza, MHLP1
Alencar, NMN1
Silva, PGB1
Alves, APNN1
Almeida, PRC1
Cunha, FQ6
Schaeffer, EM1
Mbanefo, EC2
Le, L1
Zee, R1
Banskota, N1
Ishida, K1
Pennington, LF2
Odegaard, JI2
Jardetzky, TS2
Alouffi, A2
Falcone, FH2
Hsieh, MH3
Zee, RS1
Le, LH1
Akinwale, J1
Leite, CA1
Alencar, VT1
Melo, DL1
Mota, JM2
Melo, PH1
Mourão, LT3
Wong, DV2
Magalhães, PJ2
Santos, AA2
Brito, GA8
Lima-Júnior, RC1
Ribeiro, RA9
Saito, Y1
Kumamoto, T1
Makino, Y1
Tamai, I1
Ogawa, C1
Terakado, H1
Matz, EL1
Vincentelli, F1
Caruso, G1
Figarella-Branger, D1
Macedo, FY6
Palheta, RC1
Jucá, DM1
Lima, RC2
Neto, Jde S1
Souza, MH2
Freitas, HC2
Oriá, RB1
Vale, ML1
Dobrek, Ł1
Thor, PJ1
Cohen, MH1
Dagher, R1
Griebel, DJ1
Ibrahim, A1
Martin, A1
Scher, NS1
Sokol, GH1
Williams, GA1
Pazdur, R1
Klastersky, J1
Vieira, MM2
Belarmino-Filho, JN1
Nery, EA1
Filho, JN1
Costa, AC1
Cunha, AN1
Silveira, ER1
Batista, CK1
Souza, ML1
Leitão, BT1
Kawai, K1
Takaoka, E1
Naoi, M1
Mori, K1
Minami, M1
Shimazui, T1
Akaza, H1
Lima, MV1
Ferreira, FV2
de Castro Brito, GA1
Korkmaz, A1
Topal, T1
Oter, S1
Baltazar, F1
Almeida, PR1
Távora, F1
Schmitt, FC1
Watson, RA1
Brock, N1
Pohl, J2
Stekar, J2
Fujita, J1
Matsumoto, K1
Kakizoe, T1
Murase, T1
Shinozaki, T1
Matsushita, M1
Kusawake, H1
Watanabe, H1
Arita, S1
Chigira, M1
Udagawa, E1
Matsumoto, S1
Kawaguchi, N1
Manabe, J1
Kuroda, H1
Shimoji, T1
Sakuma, H1
Satoh, T2
Matsumoto, E1
Kanno, H1
Watanabe, M1
Kikuta, A1
Suzuki, H1
Ishii, T1
Umeda, T1
Kitoh, M1
Tatezaki, S1
Goren, MP2
Markman, M1
Kennedy, A1
Webster, K1
Kulp, B1
Peterson, G1
Belinson, J1
Kuśnierczyk, H1
Konarski, L1
Kowalski, P1
Radzikowski, C1
McKenna, LM1
Goodman, TL1
Twu, NF1
Juang, CM1
Yeng, MS1
Lu, CJ1
Lai, CZ1
Chao, KC1
Campos, MC1
Santos, CC1
Figueiredo, FC1
Brühl, P1
Hoefer-Janker, H1
Scheef, W1
Vahlensieck, W1
Frustaci, S1
Foladore, S1
De Pascale, A1
Freschi, A1
Lo Re, G1
Sorio, R1
Errante, D1
Monfardini, S1
Hilgard, P1
Sakurai, M1
Saijo, N1
Shinkai, T1
Eguchi, K1
Sasaki, Y1
Tamura, T1
Sano, T1
Suemasu, K1
Jett, JR1
Andriole, GL1
Sandlund, JT1
Miser, JS1
Arasi, V1
Linehan, M1
Magrath, IT1

Reviews

5 reviews available for ifosfamide and Bleeding

ArticleYear
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
    Urology, 2017, Volume: 100

    Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Mesna

2017
Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention .
    Postepy higieny i medycyny doswiadczalnej (Online), 2012, Sep-10, Volume: 66

    Topics: Animals; Antineoplastic Agents, Alkylating; Chemoprevention; Cyclophosphamide; Cystitis; Cytoprotect

2012
Side effects of ifosfamide.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Cystitis; Drug Interactions; Heart; Hemorrhage; H

2003
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
    Cell biology and toxicology, 2007, Volume: 23, Issue:5

    Topics: Acrolein; Antineoplastic Agents; Cell Death; Cyclophosphamide; Cystitis; Cytokines; DNA Damage; Enzy

2007
Oral administration of mesna with ifosfamide.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Drug Administrat

1996

Trials

4 trials available for ifosfamide and Bleeding

ArticleYear
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cysto

2007
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1995
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Adolescent; Adult; Aged; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Male; Mesna; Middle Aged

1992
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Japanese journal of clinical oncology, 1986, Volume: 16, Issue:2

    Topics: Adult; Aged; Clinical Trials as Topic; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Lung Neopla

1986

Other Studies

33 other studies available for ifosfamide and Bleeding

ArticleYear
[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10.
    Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:8

    Topics: Animals; Cystitis; Female; Hemorrhage; Ifosfamide; Inflammation; Interleukin-10; Mesna; Mice; Signal

2023
α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclohexane Monoterpenes; Cyst

2020
Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; BK Virus; Cystitis; Hemorrhage; Humans;

2018
Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
    International immunopharmacology, 2018, Volume: 62

    Topics: Animals; Antineoplastic Agents, Alkylating; Cystitis; Drug Therapy, Combination; Female; Hemorrhage;

2018
Re: Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-Induced Hemorrhagic Cystitis.
    The Journal of urology, 2018, Volume: 200, Issue:4

    Topics: Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Protective Agents

2018
IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways.
    Scientific reports, 2019, 02-07, Volume: 9, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Cystitis; Cytokines; Egg Proteins; Gene Expression Profiling; Hel

2019
IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis.
    American journal of physiology. Renal physiology, 2019, 06-01, Volume: 316, Issue:6

    Topics: Administration, Intravesical; Animals; Basophils; Cell Line; Cell Proliferation; Cystitis; Disease M

2019
Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice.
    The Journal of urology, 2015, Volume: 194, Issue:6

    Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Drug Synergism; Hemorrhage; Ifosfamide; Inflixi

2015
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha

2016
Primary intradural Ewing's sarcoma of the cauda equina presenting with acute bleeding.
    Acta neurochirurgica, 2010, Volume: 152, Issue:3

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cauda Equina; Decompression, S

2010
Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis;

2011
Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis.
    Inflammation, 2012, Volume: 35, Issue:1

    Topics: Animals; Cyclooxygenase 2; Cystitis; Hemorrhage; Ifosfamide; Interleukin-1beta; Interleukin-4; Male;

2012
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph

2002
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:11

    Topics: Animals; Anti-Inflammatory Agents; Cystitis; Dexamethasone; Disease Models, Animal; Dose-Response Re

2003
Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats.
    Phytotherapy research : PTR, 2004, Volume: 18, Issue:2

    Topics: Animals; Asteraceae; Cyclophosphamide; Cystitis; Flavonoids; Flowers; Hemorrhage; Ifosfamide; Male;

2004
Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1

    Topics: Acrolein; Amifostine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Cystitis; Dose-Response

2007
A case of metastatic testicular cancer complicated by tumour lysis syndrome and choriocarcinoma syndrome.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Cisplatin; Drug A

2006
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:1

    Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Drug Therapy, Combination; Etorico

2008
Ifosfamide: chemotherapy with new promise and new problems for the urologist.
    Urology, 1984, Volume: 24, Issue:5

    Topics: Acetylcysteine; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Kidney Neoplasms

1984
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.
    European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:11

    Topics: Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Kinetics; Male; Rats; Rats, Inb

1981
Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation.
    Urology, 1981, Volume: 18, Issue:3

    Topics: Adult; Aged; Cyclophosphamide; Cystitis; Drug Administration Schedule; Evaluation Studies as Topic;

1981
[Combination effect of pirarubicin, ifosfamide, and vincristine sulfate in the treatment of advanced synovial sarcoma--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Cystitis; Doxorubicin; Female; Hemo

1995
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1994, Volume: 35, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu

1994
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo

1993
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Hemorrhage; Huma

1996
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Archivum immunologiae et therapiae experimentalis, 1997, Volume: 45, Issue:1

    Topics: Administration, Oral; Animals; Cystitis; Edema; Female; Hemorrhage; Ifosfamide; Injections, Intraper

1997
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:5

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Fem

1997
Treatment of primary pure angiosarcoma of ovary with multiple lung metastases: a case report.
    European journal of gynaecological oncology, 1999, Volume: 20, Issue:5-6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fema

1999
Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice.
    The Journal of urology, 2002, Volume: 167, Issue:5

    Topics: Animals; Cystitis; Enzyme Induction; Hemorrhage; Ifosfamide; Interleukin-1; Male; Mice; Nitric Oxide

2002
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
    Onkologie, 1979, Volume: 2, Issue:3

    Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa

1979
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
    Arzneimittel-Forschung, 1989, Volume: 39, Issue:6

    Topics: Acetaldehyde; Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Male; Mesna; Rats

1989
Ifosfamide and mesna.
    The Medical letter on drugs and therapeutics, 1989, Nov-03, Volume: 31, Issue:804

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cystitis; Hemorrhage; Humans; Ifosfamide; Male; Merc

1989
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag

1987